Eli Lilly and Company

(New York Stock Exchange)
Back to all articles
Very Bullish +85

Dorsey Wright & Associates Makes New Investment in Eli Lilly and ...

AI-generated analysis

πŸ“ˆ Dorsey Wright & Associates purchased a new stake of 508 shares valued at $468,000 in the first quarter.

πŸ“Š Brighton Jones LLC increased its position by 22.0% to own 9,597 shares worth $7.4 million in the fourth quarter.

πŸ“‰ Revolve Wealth Partners LLC and Schnieders Capital Management LLC also increased their stakes by 2.8% and 16.7% respectively.

πŸ’° Flow Traders U.S. LLC and Nebula Research & Development LLC acquired new stakes valued at approximately $356,000 and $749,000 in the second quarter.

🏦 Berenberg Bank raised its price target from $1,050 to $1,135 with a 'hold' rating on June 22nd.

πŸš€ Wolfe Research reiterated an 'outperform' rating and issued a $1,350 target price on May 21st.

πŸ“ˆ UBS Group boosted its target price from $1,250 to $1,425 with a 'buy' rating on July 13th.

πŸ’΅ Citigroup upped its price target from $1,500 to $1,600 and maintained a 'buy' rating.

πŸ‡¨πŸ‡¦ Royal Bank of Canada raised its target from $1,250 to $1,500 with an 'outperform' rating on July 8th.

πŸ“Š Analyst consensus shows 28 Buy/Strong Buy ratings versus one Sell rating with an average target of $1,283.64.

πŸ’Ή Eli Lilly reported $8.55 EPS for the quarter, beating the consensus estimate of $6.97 by $1.58.

πŸ“ˆ Revenue reached $19.80 billion, a 55.5% increase year-over-year against estimates of $17.82 billion.

πŸ’° The company achieved a net margin of 34.98% and a return on equity of 105.77%.

πŸ“… Full-year 2026 guidance is set between $35.50 and $37.00 EPS, above analyst expectations of $34.55.

πŸ’Έ A quarterly dividend of $1.73 per share will be paid on September 10th to shareholders of record on August 14th.

πŸ“‰ The stock trades at a P/E ratio of 41.85 with a market cap of $1.11 trillion.

πŸ“Š Technical analysis shows the stock trading above its 50-day moving average of $1,118.87 and 200-day average of $1,036.80.

🌍 The company operates globally with a presence in North America, Europe, Asia, and emerging markets.

πŸ‘€ CEO David A. leads the global pharmaceutical company founded in 1876 and headquartered in Indianapolis.

πŸ“‰ Hedge funds and institutional investors collectively own 82.53% of the company's outstanding stock.

Bullish Signals
  • Eli Lilly significantly beat quarterly earnings estimates, reporting $8.55 EPS versus a consensus of $6.97.
  • Revenue surged 55.5% year-over-year to $19.80 billion, exceeding analyst expectations of $17.82 billion.
  • The company demonstrated exceptional profitability with a net margin of 34.98% and a return on equity of 105.77%.
  • Multiple major brokerages including UBS Group, Citigroup, and Royal Bank of Canada raised their price targets and maintained 'buy' or 'outperform' ratings.
  • Analyst consensus is overwhelmingly positive with 28 Buy/Strong Buy ratings against only one Sell rating.
  • The stock trades above both its 50-day and 200-day moving averages, indicating strong technical momentum.
  • Institutional investors are actively accumulating shares, with Dorsey Wright & Associates, Brighton Jones LLC, and others increasing or initiating positions.
  • The company has set robust full-year 2026 guidance of $35.50-$37.00 EPS, which exceeds current analyst expectations of $34.55.
Full Analysis
Dorsey Wright & Associates increased its stake in Eli Lilly and Company (NYSE: LLY) by purchasing 508 shares valued at approximately $468,000 during the first quarter. Other institutional investors also adjusted their holdings, with Brighton Jones LLC increasing its position by 22.0% to own 9,597 shares worth $7.4 million, and Revolve Wealth Partners LLC adding 40 shares. Schnieders Capital Management LLC increased its stake by 16.7%, while Flow Traders U.S. LLC and Nebula Research & Development LLC acquired new stakes valued at roughly $356,000 and $749,000 respectively in the second quarter. Major brokerages have recently upgraded their outlook for Eli Lilly, citing strong performance. Berenberg Bank raised its price target from $1,050 to $1,135 with a 'hold' rating, while Wolfe Research maintained an 'outperform' rating with a $1,350 target. UBS Group increased its target to $1,425 with a 'buy' rating, and Citigroup raised its target to $1,600. Royal Bank of Canada also boosted its target to $1,500 with an 'outperform' rating. Collectively, analysts hold 28 'Buy' or 'Strong Buy' ratings against just one 'Sell', reflecting a consensus average target price of $1,283.64. Eli Lilly reported robust financial results for the quarter ended April 30, beating earnings estimates significantly. The company posted $8.55 EPS compared to the consensus of $6.97, driven by revenue of $19.80 billion which represented a 55.5% year-over-year increase. Key metrics included a net margin of 34.98% and a return on equity of 105.77%. The firm has set full-year 2026 guidance between $35.50 and $37.00 EPS, while the current quarter's consensus estimate stands at $34.55. The stock currently trades with a market capitalization of $1.11 trillion and a P/E ratio of 41.85. Technical indicators show the stock trading above its 50-day moving average of $1,118.87 and its 200-day moving average of $1,036.80. The company recently announced a quarterly dividend of $1.73 per share, payable on September 10th to shareholders of record on August 14th, representing an annualized yield of 0.6% and a payout ratio of 24.58%.